Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer




+44 (0)20 3313 3759eric.aboagye




Mrs Maureen Francis +44 (0)20 7594 2793




GN1Commonwealth BuildingHammersmith Campus






BibTex format

author = {Fu, R and Carroll, L and Yahioglu, GK and Aboagye, E and Miller, P},
doi = {10.1002/cmdc.201800624},
journal = {ChemMedChem},
pages = {2466--2478},
title = {Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications},
url = {},
volume = {13},
year = {2018}

RIS format (EndNote, RefMan)

AB - Antibodies have long been recognised as potent vectors for carrying diagnostic medical radionuclides, contrast agents and optical probes to diseased tissue for imaging. The area of ImmunoPET combines the use of positron emission tomography (PET) imaging with antibodies to improve the diagnosis, staging and monitoring of diseases. Recent developments in antibody engineering and PET radiochemistry have led to a new wave of experimental ImmunoPET imaging agents that are based on a range of antibody fragments and affibodies. In contrast to full antibodies, engineered affibody proteins and antibody fragments such as minibodies, diabodies, singlechain variable region fragments (scFvs), and nanobodies are much smaller but retain the essential specificities and affinities of full antibodies in addition to more desirable pharmacokinetics for imaging. Herein, recent key developments in the PET radiolabelling strategies of antibody fragments and related affibody molecules are highlighted, along with the main PET imaging applications of overexpressed antigenassociated tumours and immune cells.
AU - Fu,R
AU - Carroll,L
AU - Yahioglu,GK
AU - Aboagye,E
AU - Miller,P
DO - 10.1002/cmdc.201800624
EP - 2478
PY - 2018///
SN - 1860-7187
SP - 2466
TI - Antibody fragment and affibody immunoPET imaging agents: radiolabelling strategies and applications
T2 - ChemMedChem
UR -
UR -
VL - 13
ER -